Replies to post #82565 on Biotech Values

[medchal]

"Why isn't the share price rocketing up?" I have no idea and don't even follow this company, but I am interested in how the F. D. A. may choose to apply and interpret its new regulations on provision of drugs pre-approval. The guidelines under which companies might charge for drugs so furnished seem pretty stiff. There's no mention in the article cited as to whether the company can charge, so I'll assume (as someone else surmised or knew--?) that it may not. With F. D. A., interpretation is everything: The rules seldom are definitive of what will happen. I find it encouraging that the F. D. A. says that it may permit dispensing of drugs under certain conditions prior to approval. This almost instant example also looks encouraging, but the idea that there could be any great possibility of reimbursement for provision of experimental drugs still seems remote and unproven. I'll simply be watching for further examples of the implementation of this rule.

Thanks to all for the responses.

[genisi]

PLX share price did go up since GENZ announced on 6/16 that the Allston facility, would be shut down temporarily due to virus contamination. Implications are that docs and patients can get familiar with both drugs from PLX and Shire before commercial approval. This should only last a couple of months with no direct economic benefit but it is a good PR on GENZ's expense.